Market Spotlight: Glaucoma

  • ID: 4421396
  • Report
  • 53 pages
  • Datamonitor Healthcare
1 of 3
This Market Spotlight report covers the Glaucoma market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Note: Product cover images may vary from those shown
2 of 3
KEY TAKEAWAYS

DISEASE BACKGROUND
Subtypes

TREATMENT
Eye drops
Oral medications

EPIDEMIOLOGY

MARKETED DRUGS
Approvals by country

PIPELINE DRUGS

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS
Aerie's Rhopressa Approved Early For Glaucoma, 2018 Launch Planned
Glaukos Submits PMA For iStent, Second-Generation MIGS Device For Treating Glaucoma
Aerie's M&A Potential Rises As Roclatan Passes Second Phase III Glaucoma Test
MIXiii Biomed 2017: Aging, Technology & Robotics In The Digital World
Bausch & Lomb/Nicox Eye Drug Resubmission Is Assigned August Review Goal
Aerie's Rhopressa Lands At FDA Again
FDA Seeks Plant Clean-Up Before Approving Eye Drug
Aerie Grounds Rhopressa
Regeneron Partnering With Ocular May Provide Needed Tech Validation
New Combinations
US Approvals Analysis

LICENSING AND ASSET ACQUISITION DEALS
Santen, TwoXAR Collaborate In Ophthalmics
Otsuka/Acucela (No Deal)
Alcon Puts Money Where Mouth Is With Glaucoma Device Buy

PARENT PATENTS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE
Sponsors by status
Sponsors by phase
Recent events

BIBLIOGRAPHY
Prescription information

APPENDIX

List of Figures
Figure 1: Prevalence trends in glaucoma, 2016-25
Figure 2: Prevalent cases of glaucoma, by region, 2017
Figure 3: Overview of pipeline drugs for glaucoma in the US
Figure 4: Pipeline drugs for glaucoma, by company
Figure 5: Pipeline drugs for glaucoma, by drug type
Figure 6: Pipeline drugs for glaucoma, by classifications
Figure 7: Key upcoming events in glaucoma
Figure 8: Licensing and asset acquisition deals in glaucoma
Figure 9: Parent patents in glaucoma
Figure 10: Clinical trials in glaucoma
Figure 11: Top 10 drugs for clinical trials in glaucoma
Figure 12: Top 10 companies for clinical trials in glaucoma
Figure 13: Trial locations in glaucoma
Figure 14: Glaucoma trials status
Figure 15: Glaucoma trials sponsors, by phase

List of Tables
Table 1: Prevalent cases of glaucoma, 2016-25
Table 2: Prevalence proportions in glaucoma, 2016-25
Table 3: Marketed drugs for glaucoma
Table 4: Approvals by country for glaucoma
Table 5: Pipeline drugs for glaucoma in the US
Table 6: Historic global sales, by drug ($m), 2012-16
Table 7: Forecasted global sales, by drug ($m), 2017-22
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll